> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/dosing-bioavailability-and-human-scaling.md).
# Dosing, Bioavailability, and Human Scaling
The strongest **RET-style** melatonin claims come from animal and cell studies, not human oncology trials.
That means dose discussion has to separate **measured evidence** from **extrapolated human-equivalent estimates**.
If you need the formulation page, go to [DIY Liposomal Melatonin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin.md).
### The two anchor studies
#### In vivo mouse study
Benaiges et al. used **40 mg/kg intraperitoneal melatonin** in tumour-bearing mice.
That exposure suppressed tumour growth and was linked to a transient mitochondrial ROS burst.
#### In vitro cell study
Florido et al. exposed head-and-neck cancer cells to **0.5 to 1 mM melatonin**.
ROS rose within the first 1 to 3 hours, then preceded apoptosis.
### The dose-dependent immune split still matters
The source literature points to two very different melatonin use cases.
#### Moderate adjunct range
This is the **human oral oncology** range.
It usually means about **10 to 40 mg nightly** by mouth.
This range is generally discussed as:
* circadian-supportive
* **Th1-supportive** or at least Th1-compatible
* compatible with the Lissoni-style adjunct literature
#### Very high RET-aimed exposure
This is the **mechanistic high-exposure** range.
It aims at something closer to the mouse-equivalent systemic exposure.
That is where the RET and ROS discussion sits.
It is also where concern about **Th1 blunting**, broader immunosuppression, sedation, endocrine load, and CYP effects rises.
### What counts as a very high pharmacological exposure
The animal-to-human scaling from **40 mg/kg in mice** gives about **3.24 mg/kg in humans**.
That works out to roughly:
* **160 mg systemic exposure** for a 50 kg person
* **230 mg systemic exposure** for a 70 kg person
A practical shorthand is a target near **225 mg reaching the bloodstream**.
That is an exposure estimate, not a proven human treatment target.
### Why oral dose and systemic dose are not the same
What matters mechanistically is not what is swallowed.
What matters is what actually reaches circulation.
#### Plain powder or standard tablets
If oral bioavailability is near **10%**, reaching about **225 mg systemically** may require roughly **2 to 2.5 grams swallowed**.
#### Liposomal or alcohol-solubilised liquid
If absorption is closer to **40%**, the same systemic target may be reached with roughly **600 mg swallowed**.
These are alternative routes to a similar estimated exposure.
They are not meant to be combined.
### Practical interpretation
Three practical points matter here.
* Better absorption lowers the total oral dose needed.
* Poor absorption pushes people toward gram-level intake.
* Gram-level intake raises tolerability, sedation, endocrine, and interaction questions much faster.
If only raw powder is used, roughly **2 to 2.5 g** may be needed to approach the mouse-equivalent internal exposure.
If a higher-efficiency liposomal or solubilised system is used, the swallowed amount can be much lower.
For formulation context, see [DIY Liposomal Melatonin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin.md).
### Better delivery changes the arithmetic
The key point is that oral dose and internal exposure are not interchangeable.
A better-formulated liquid may reach a target exposure with far less material swallowed.
A poorly absorbed powder may require several times more.
That difference matters because the body responds to both the systemic exposure and the burden of the formulation used to get there.
### Gram-level powder is a different practical problem
Swallowing **2 to 2.5 grams** of plain powder is not just a dosing calculation.
It creates a separate tolerability question.
Sedation, gastrointestinal tolerance, product quality, and interaction risk all become more relevant at that scale.
This is one reason the route and formulation question cannot be treated as a minor detail.
### The uncertain middle zone
One practical problem is the range between classic human adjunct use and estimated mouse-equivalent systemic exposure.
Someone can sit well above the **20 to 40 mg nightly** human range without clearly reaching the exposure that the RET argument is built on.
That middle zone is hard to interpret with confidence.
It may be too low for the intended mitochondrial pulse logic, yet high enough to move outside the better-supported adjunct window.
A practical example is **400 mg plain powder orally**.
That may still fall well short of the estimated systemic RET target while moving above the classic oral human adjunct range.
### What can and cannot be claimed
The current evidence supports three careful claims.
* Mouse and cell studies support a high-exposure ROS mechanism.
* Human oral adjunct studies support a moderate-dose clinical-support zone.
* The bridge between those two worlds remains extrapolated.
{% hint style="warning" %}
No human cancer trial has confirmed that an estimated 225 mg systemic exposure reproduces the mouse tumour-control effect.
{% endhint %}
### Caveats that matter
1. **Route matters.** Intraperitoneal mouse dosing is not the same as oral human dosing.
2. **Formulation matters.** Liposomal and solubilised products vary widely.
3. **Absorption varies.** Gut handling, food, and product quality change real exposure.
4. **Side effects scale up.** Sedation, endocrine shifts, and CYP1A2 interaction risk become more relevant at higher intakes.
5. **The immune trade-off matters.** Higher exposure is not automatically better if the goal is Th1 support.
### Bottom line
The high-dose mitochondrial model is exposure-driven.
The current human discussion is therefore about **approximation**, not confirmation.
That is why moderate clinical adjunct use and very-high-dose RET-style use should be treated as two different strategies.
### Related pages
* [Melatonin in Oncology - Study Notes](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes.md) — the hub page that ties together the mitochondria, dosing, immune, phase-separation, and fibrosis sections
* [DIY Liposomal Melatonin](/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin.md) — formulation notes, storage, costing, and practical liposomal-delivery context
* [High-Dose Mitochondria, RET, and ROS](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/high-dose-mitochondria-ret-and-ros.md) — the mechanistic RET, ROS, uncoupling, and apoptosis sequence behind the high-dose claim
* [Moderate-Dose Immune Effects and Timing](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/moderate-dose-immune-effects-and-timing.md) — the human oral adjunct literature, Th1 logic, and timing framework
* [Phase Separation in Oncology](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/phase-separation-in-oncology.md) — the oncogenic-condensate model, its three levers, and the chronotherapy angle
* [Fibrotic Drivers and the 26-Gene Signature](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/fibrotic-drivers-and-the-26-gene-signature.md) — how the condensate story overlaps with EMT, fibrosis, YAP/TAZ, β-catenin, and stromal remodelling
* [Addendum — Dosing, Th1/Th2, and Recalibration](/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/addendum-dosing-th1-th2-and-recalibration.md) — why continuous high-dose oral use may work against the immune goal, and how to reassess it
### Key references
* Benaiges et al. 2023\
* Florido et al. 2022\
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/melatonin-in-oncology-study-notes/dosing-bioavailability-and-human-scaling.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.